【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 18
2 Introduction 19
2.1 Auto-Immune Diseases Overview 19
3 Products under Development 20
3.1 Auto-Immune Diseases – Pipeline Products by Stage of Development 20
3.2 Auto-Immune Diseases – Pipeline Products by Territory 21
3.3 Auto-Immune Diseases – Pipeline Products by Regulatory Path 22
3.4 Auto-Immune Diseases – Pipeline Products by Estimated Approval Date 23
4 Auto-Immune Diseases – Pipeline Products under Development by Companies 24
4.1 Auto-Immune Diseases Companies – Pipeline Products by Stage of Development 24
4.2 Auto-Immune Diseases – Pipeline Products by Stage of Development 28
5 Auto-Immune Diseases Companies and Product Overview 35
5.1 Adaptive Biotechnologies Corporation Company Overview 35
5.1.1 Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview 35
5.2 Agena Bioscience, Inc Company Overview 36
5.2.1 Agena Bioscience, Inc Pipeline Products & Ongoing Clinical Trials Overview 36
5.3 Albert-Ludwigs-Universitat Freiburg Company Overview 37
5.3.1 Albert-Ludwigs-Universitat Freiburg Pipeline Products & Ongoing Clinical Trials Overview 37
5.4 Alere Inc. Company Overview 40
5.4.1 Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.5 Amarantus Bioscience Holdings, Inc. Company Overview 43
5.5.1 Amarantus Bioscience Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.6 Amdix B.V. Company Overview 46
5.6.1 Amdix B.V. Pipeline Products & Ongoing Clinical Trials Overview 46
5.7 Analyticon Biotechnologies AG Company Overview 47
5.7.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 47
5.8 apDia n.v. Company Overview 48
5.8.1 apDia n.v. Pipeline Products & Ongoing Clinical Trials Overview 48
5.9 Autoimmune Technologies, LLC Company Overview 49
5.9.1 Autoimmune Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 49
5.10 Beckman Coulter, Inc. Company Overview 55
5.10.1 Beckman Coulter, Inc. Pipeline Products & Ongoing Clinical Trials Overview 55
5.11 BG Medicine, Inc. Company Overview 57
5.11.1 BG Medicine, Inc. Pipeline Products & Ongoing Clinical Trials Overview 57
5.12 Biocortech Company Overview 59
5.12.1 Biocortech Pipeline Products & Ongoing Clinical Trials Overview 59
5.13 Biogen, Inc. Company Overview 60
5.13.1 Biogen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 60
5.14 Biomedal S.L. Company Overview 62
5.14.1 Biomedal S.L. Pipeline Products & Ongoing Clinical Trials Overview 62
5.15 Biomerica, Inc. Company Overview 66
5.15.1 Biomerica, Inc. Pipeline Products & Ongoing Clinical Trials Overview 66
5.16 Bionure Farma, S.L. Company Overview 70
5.16.1 Bionure Farma, S.L. Pipeline Products & Ongoing Clinical Trials Overview 70
5.17 Bio-Rad Laboratories, Inc. Company Overview 71
5.17.1 Bio-Rad Laboratories, Inc. Pipeline Products & Ongoing Clinical Trials Overview 71
5.18 BioRap Technologies Ltd. Company Overview 73
5.18.1 BioRap Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 73
5.19 Boston University Company Overview 74
5.19.1 Boston University Pipeline Products & Ongoing Clinical Trials Overview 74
5.20 CareDx, Inc. Company Overview 75
5.20.1 CareDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
5.21 CD Diagnostics, Inc. Company Overview 77
5.21.1 CD Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 77
5.22 Chronix Biomedical, Inc. Company Overview 78
5.22.1 Chronix Biomedical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 78
5.23 Co-Diagnostics HBDC, Inc. Company Overview 81
5.23.1 Co-Diagnostics HBDC, Inc. Pipeline Products & Ongoing Clinical Trials Overview 81
5.24 Crescendo Bioscience, Inc. Company Overview 82
5.24.1 Crescendo Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
5.25 Digna Biotech, S.L. Company Overview 86
5.25.1 Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 86
5.26 Durin Technologies, Inc. Company Overview 90
5.26.1 Durin Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 90
5.27 Enterome Bioscience SA Company Overview 91
5.27.1 Enterome Bioscience SA Pipeline Products & Ongoing Clinical Trials Overview 91
5.28 Ezose Sciences Inc. Company Overview 93
5.28.1 Ezose Sciences Inc. Pipeline Products & Ongoing Clinical Trials Overview 93
5.29 Flamentera AG Company Overview 94
5.29.1 Flamentera AG Pipeline Products & Ongoing Clinical Trials Overview 94
5.30 Genalyte, Inc. Company Overview 95
5.30.1 Genalyte, Inc. Pipeline Products & Ongoing Clinical Trials Overview 95
5.31 Genentech, Inc. Company Overview 96
5.31.1 Genentech, Inc. Pipeline Products & Ongoing Clinical Trials Overview 96
5.32 GeNeuro SA Company Overview 99
5.32.1 GeNeuro SA Pipeline Products & Ongoing Clinical Trials Overview 99
5.33 Glycominds Ltd. Company Overview 101
5.33.1 Glycominds Ltd. Pipeline Products & Ongoing Clinical Trials Overview 101
5.34 Grifols, S.A. Company Overview 102
5.34.1 Grifols, S.A. Pipeline Products & Ongoing Clinical Trials Overview 102
5.35 Hannover Medical School Company Overview 104
5.35.1 Hannover Medical School Pipeline Products & Ongoing Clinical Trials Overview 104
5.36 Helmholtz Centre for Infection Research Company Overview 105
5.36.1 Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview 105
5.37 HOB Biotech Group Co., Ltd. Company Overview 106
5.37.1 HOB Biotech Group Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 106
5.38 Hospital for Special Surgery Company Overview 107
5.38.1 Hospital for Special Surgery Pipeline Products & Ongoing Clinical Trials Overview 107
5.39 Hycor Biomedical Inc. Company Overview 108
5.39.1 Hycor Biomedical Inc. Pipeline Products & Ongoing Clinical Trials Overview 108
5.40 Ignyta, Inc. Company Overview 110
5.40.1 Ignyta, Inc. Pipeline Products & Ongoing Clinical Trials Overview 110
5.41 ImmusanT, Inc. Company Overview 114
5.41.1 ImmusanT, Inc. Pipeline Products & Ongoing Clinical Trials Overview 114
5.42 Innobiochips Company Overview 115
5.42.1 Innobiochips Pipeline Products & Ongoing Clinical Trials Overview 115
5.43 INOVA Diagnostics, Inc. Company Overview 116
5.43.1 INOVA Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 116
5.44 Institut National de la Sante et de la Recherche Medicale Company Overview 126
5.44.1 Institut National de la Sante et de la Recherche Medicale Pipeline Products & Ongoing Clinical Trials Overview 126
5.45 Is Diagnostics Company Overview 127
5.45.1 Is Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 127
5.46 LineaGen, Inc. Company Overview 128
5.46.1 LineaGen, Inc. Pipeline Products & Ongoing Clinical Trials Overview 128
5.47 Lophius Biosciences GmbH Company Overview 129
5.47.1 Lophius Biosciences GmbH Pipeline Products & Ongoing Clinical Trials Overview 129
5.48 Louisville Bioscience, Inc. Company Overview 130
5.48.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 130
5.49 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Company Overview 134
5.49.1 Max-Delbruck-Centrum fur Molekulare Medizin (MDC) Pipeline Products & Ongoing Clinical Trials Overview 134
5.50 Medica Corporation Company Overview 135
5.50.1 Medica Corporation Pipeline Products & Ongoing Clinical Trials Overview 135
5.51 Metabolomic Technologies Inc. Company Overview 138
5.51.1 Metabolomic Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 138
5.52 Metanomics Health GmbH Company Overview 142
5.52.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 142
5.53 MSDx, Inc. Company Overview 143
5.53.1 MSDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 143
5.54 Myriad Genetics, Inc. Company Overview 147
5.54.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 147
5.55 Nanosphere, Inc. Company Overview 149
5.55.1 Nanosphere, Inc. Pipeline Products & Ongoing Clinical Trials Overview 149
5.56 Neuro Vigor, LLC Company Overview 151
5.56.1 Neuro Vigor, LLC Pipeline Products & Ongoing Clinical Trials Overview 151
5.57 Northwestern University Company Overview 152
5.57.1 Northwestern University Pipeline Products & Ongoing Clinical Trials Overview 152
5.58 NoToPharm s.r.l. Company Overview 154
5.58.1 NoToPharm s.r.l. Pipeline Products & Ongoing Clinical Trials Overview 154
5.59 NOWDiagnostics Company Overview 162
5.59.1 NOWDiagnostics Pipeline Products & Ongoing Clinical Trials Overview 162
5.60 OmniBiome Therapeutics Inc. Company Overview 163
5.60.1 OmniBiome Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 163
5.61 One Way Liver Genomics, S.L. Company Overview 164
5.61.1 One Way Liver Genomics, S.L. Pipeline Products & Ongoing Clinical Trials Overview 164
5.62 OPKO Health, Inc. Company Overview 166
5.62.1 OPKO Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 166
5.63 Oxford Gene Technology Limited Company Overview 168
5.63.1 Oxford Gene Technology Limited Pipeline Products & Ongoing Clinical Trials Overview 168
5.64 Oxford Immunotec Limited Company Overview 169
5.64.1 Oxford Immunotec Limited Pipeline Products & Ongoing Clinical Trials Overview 169
5.65 Pediatric Bioscience, LLC Company Overview 170
5.65.1 Pediatric Bioscience, LLC Pipeline Products & Ongoing Clinical Trials Overview 170
5.66 Progentec Diagnostics, Inc. Company Overview 171
5.66.1 Progentec Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 171
5.67 Protagen AG Company Overview 172
5.67.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 172
5.68 ProteinLogic Ltd Company Overview 182
5.68.1 ProteinLogic Ltd Pipeline Products & Ongoing Clinical Trials Overview 182
5.69 Quanterix Corporation Company Overview 183
5.69.1 Quanterix Corporation Pipeline Products & Ongoing Clinical Trials Overview 183
5.70 Regulus Therapeutics Inc. Company Overview 184
5.70.1 Regulus Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 184
5.71 Rice University Company Overview 186
5.71.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 186
5.72 Roche Diagnostics International Ltd. Company Overview 187
5.72.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview 187
5.73 Shuwen Biotech Co. Ltd. Company Overview 193
5.73.1 Shuwen Biotech Co. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 193
5.74 Singulex, Inc. Company Overview 194
5.74.1 Singulex, Inc. Pipeline Products & Ongoing Clinical Trials Overview 194
5.75 SomaLogic, Inc. Company Overview 195
5.75.1 SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 195
5.76 Southern Illinois University Carbondale Company Overview 196
5.76.1 Southern Illinois University Carbondale Pipeline Products & Ongoing Clinical Trials Overview 196
5.77 SQI Diagnostics Inc. Company Overview 198
5.77.1 SQI Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 198
5.78 The Johns Hopkins University Company Overview 207
5.78.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 207
5.79 The Walter and Eliza Hall Institute of Medical Research Company Overview 210
5.79.1 The Walter and Eliza Hall Institute of Medical Research Pipeline Products & Ongoing Clinical Trials Overview 210
5.80 TheraDiag SA Company Overview 211
5.80.1 TheraDiag SA Pipeline Products & Ongoing Clinical Trials Overview 211
5.81 Thermo Fisher Scientific Inc. Company Overview 213
5.81.1 Thermo Fisher Scientific Inc. Pipeline Products & Ongoing Clinical Trials Overview 213
5.82 Toscana Biomarkers Srl Company Overview 237
5.82.1 Toscana Biomarkers Srl Pipeline Products & Ongoing Clinical Trials Overview 237
5.83 Univalue Valorizacion, S.L. Company Overview 243
5.83.1 Univalue Valorizacion, S.L. Pipeline Products & Ongoing Clinical Trials Overview 243
5.84 University of California, San Francisco Company Overview 244
5.84.1 University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview 244
5.85 University of Chicago Company Overview 247
5.85.1 University of Chicago Pipeline Products & Ongoing Clinical Trials Overview 247
5.86 University of Colorado Company Overview 248
5.86.1 University of Colorado Pipeline Products & Ongoing Clinical Trials Overview 248
5.87 University of Florida Company Overview 249
5.87.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview 249
5.88 University of Manchester Company Overview 250
5.88.1 University of Manchester Pipeline Products & Ongoing Clinical Trials Overview 250
5.89 University of Oxford Company Overview 252
5.89.1 University of Oxford Pipeline Products & Ongoing Clinical Trials Overview 252
5.90 University of Pecs Company Overview 256
5.90.1 University of Pecs Pipeline Products & Ongoing Clinical Trials Overview 256
5.91 University Rovira i Virgili Company Overview 257
5.91.1 University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview 257
5.92 US Biomarkers, Inc. Company Overview 258
5.92.1 US Biomarkers, Inc. Pipeline Products & Ongoing Clinical Trials Overview 258
5.93 Washington University in St. Louis Company Overview 259
5.93.1 Washington University in St. Louis Pipeline Products & Ongoing Clinical Trials Overview 259
5.94 XAir Diagnostics B.V. Company Overview 260
5.94.1 XAir Diagnostics B.V. Pipeline Products & Ongoing Clinical Trials Overview 260
5.95 XEPTAGEN SpA Company Overview 261
5.95.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview 261
5.96 Yale University Company Overview 262
5.96.1 Yale University Pipeline Products & Ongoing Clinical Trials Overview 262
6 Auto-Immune Diseases- Recent Developments 263
7 Appendix 292
7.1 Methodology 292
7.2 About GlobalData 294
7.3 Contact Us 295
7.4 Disclaimer 295
【レポート販売概要】
■ タイトル：世界の自己免疫疾患用装置開発動向：医療機器パイプライン分析2015■ 英文：Auto-Immune Diseases - Medical Devices Pipeline Assessment, 2015
■ 発行日：2016年1月5日
■ 調査会社：GlobalData
■ 商品コード：GDME0148EPD
■ 調査対象地域：グローバル
- 防腐剤・殺菌剤の世界市場2017-2021ABSTRACTAbout Antiseptic and Disinfectant Products A germicide is a product or an agent that is used to kill microorganisms such as bacteria, viruses, fungi, and algae. The germicides used to kill germs on the surface of any non-living surfaces are called disinfectants, and those used on any living surfaces are called antiseptics. Disinfectants and antiseptics are used by different end-users such …
- 世界のグルテンフリー食品市場Gluten is a protein present in wheat, barley, rye and their derivatives. Some people are found to be sensitive to gluten and show mild symptoms of chronic diarrhea, vomiting, etc., while some show typical symptoms of the condition named Coeliac disease. The gluten-free market has witnessed a revolution where these products were seen as a specialty niche product and today they are known as mainstre …
- ゴムタイヤ式門型（RTG）クレーンの世界市場分析：タイプ別（8輪車、16輪車）、電源別（ディーゼル、電気、ハイブリッド）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA）、セグメント予測、2014-2025The global rubber-tired gantry (RTG) crane market is expected to reach USD 1.64 billion by 2025, according to a new study by Grand View Research, Inc. Advancements in technologies, such as Active Load System (ALS), are expected to fuel the market growth over the forecast period. RTGs equipped with ALS technology help in increasing the stability of the container during transportation.The increasing …
- 血行動態モニタリング装置（医療機器）のグローバル新興国市場（2012-2018）BRICSS Hemodynamic Monitoring Devices market value is expected to reach US$281 million by 2016, primarily supported by the product types - Cardiac Output Monitoring Devices and Pulmonary Artery Catheters. China accounts for nearly 24% of the market share and India claims more than 24%. In terms of CAGR, India is the fastest growing region while China and South Korea are just behind. Among the prod …
- マスターバッチの世界市場：ホワイトマスターバッチ、ブラックマスターバッチ、カラーマスターバッチ、添加剤マスターバッチ、フィラーマスターバッチThe masterbatch market is projected to reach USD 12.61 Billion by 2020, registering a CAGR of 7.0% between 2015 and 2020. The global masterbatch market is driven by increased demand from the end-use industries such as packaging, building & construction, consumer goods, automotive, and textiles. Asia-Pacific, with its growing economy and rapidly expanding commercial and industrial base is projected …
- 加齢黄斑変性（AMD）及びその他の網膜疾患治療薬の世界市場：滲出型（ウェット型）、萎縮型（ドライ型）、糖尿病性網膜症Analysis of revenues and R&D prospects for those eye drugs – you explore potentials What’s the future for treating disorders of the retina? Visiongain’s updated study forecasts those pharma revenues. There you find outlooks for sales growth in that industry. You also explore trends, technologies, therapies and opportunities. That report gives revenue predictions to 2025 at overall world market, su …
- Gonorrhea：医療検査市場2014The report presents a detailed analysis of the Gonorrhea diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Gonorrhea definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Com …
- POS端末の世界市場：製品別（固定型、携帯型）、コンポーネント別（ハードウェア、ソフトウェア、サービス）、導入別、サービス別、用途別、地域別予測Global Point-of-Sale (POS) Terminals Market valued approximately USD 54.7 billion in 2016 is anticipated to grow with a healthy growth rate of more than 11.20% over the forecast. The global point-of-sale (POS) terminal market features a fairly fragmented landscape with an elevated level of competition among players of all types, notes Transparency Market Research (TMR). Over the years, the competi …
- Hadoopビッグデータ分析の世界市場予測（～2021）：構成要素別（ソリューション、サービス）、用途別、産業別、地域別The Hadoop big data analytics market is projected to grow from USD 6.71 Billion in 2016 to USD 40.69 Billion by 2021, at a CAGR of 43.4% during the forecast period. Growth in this market is mainly attributed to the increasing volume of big data and growing need for big data analytics. With increase in the volume of big data, companies are looking for ways to analyze and process it quickly and econ …
- 非破壊検査（NDT）装置及びサービスの世界市場：超音波探傷試験、電磁誘導試験、渦電流探傷試験、浸透探傷試験、放射線透過試験などNon-Destructive Testing (NDT) is the process of inspecting, testing, or evaluating materials, components, or assemblies for discontinuities or differences in characteristics without altering the original attributes. It has the property to determine the discontinuities and differences in material characteristics. Non-Destructive Testing (NDT) is broadly divided into NDT equipment and NDT services m …
- グローバルにおけるスマートグリッド市場動向：April 2014Smart Grid Review - April 2014 Summary A substantial number of smart grid developments took place in March 2014, including product launches, fundraising events and the announcement and completion of contracts and projects. Four major acquisitions took place in March. One was Rolls-Royce Holdings, which offers integrated power systems and services, acquiring the surplus 50% interest in Rolls-Royce …
- グローバルにおけるオンライン小売（インターネット通販）市場動向With an increase in the adoption of social media around the world, there has been tremendous growth in the global online retail industry. Shoppers today are tending to shop online more and more often than ever before. Instead of having to wait in checkout lines or maneuver around a crowded shopping center, people prefer to shop from the comfort of their own home. With online companies aiming to at …
- インテリジェント遠隔端末装置（RTU）の世界市場2017-2021About Intelligent RTU RTU is a control device that helps the master device, SCADA, to monitor and communicate with devices in the grid placed in different geographical locations. RTUs can be used in a broad range of electrical and process automation devices wherever SCADA is required to monitor and control the equipment. They are used to collect data from field equipment and communicate the comman …
- 世界の炭化珪素(SiC)市場2015The Global Silicon Carbide (SiC) Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Silicon Carbide (SiC) industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Silicon Carbide (SiC) market analysis is provided for the international markets including deve …
- ヘルスケアCRMの世界市場分析：用途別（コミュニティー・アウトリーチ、ケース・コーディネーション･マネジメント、リレーションシップ・マネジメント）、技術別（クラウドベース、予測、協力的）、セグメント予測、2014-2025The global healthcare CRM market is expected to reach USD 17.4 billion by 2025, according to a new study by Grand View Research Inc. Rising demand for workflow automation and single platform for tracking medical information provides coordination of patient care, service and timely delivery which is expected to drive the industry growth. The healthcare payers, providers and life science companies a …
